Actinogen Medical Limited (ATGGF)
ATGGF Stock Price Chart
Explore Actinogen Medical Limited interactive price chart. Choose custom timeframes to analyze ATGGF price movements and trends.
ATGGF Company Profile
Discover essential business fundamentals and corporate details for Actinogen Medical Limited (ATGGF) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
18 Sept 2018
Employees
—
Website
https://www.actinogen.com.auCEO
Steven G. Gourlay ), FRACP, MBBS (M.D.,
Description
Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It is developing Xanamem, an inhibitor of the 11ß-HSD1 enzyme, which is in Phase 2 clinical trials that achieves target engagement in the central nervous system, Alzheimer's disease, depression with cognitive impairment, and anxiety, sleep, and behavioral problems in fragile X syndrome. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. Actinogen Medical Limited was incorporated in 1999 and is based in Sydney, Australia.
ATGGF Financial Timeline
Browse a chronological timeline of Actinogen Medical Limited corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 23 Feb 2026
Upcoming earnings on 23 Feb 2026
Earnings released on 25 Aug 2025
Earnings released on 25 Aug 2025
Earnings released on 24 Feb 2025
EPS came in at -$0.00 , while revenue for the quarter reached $151.21K .
Earnings released on 29 Oct 2024
Earnings released on 29 Aug 2024
EPS came in at -$0.00 , while revenue for the quarter reached $3.01M .
Earnings released on 30 Apr 2024
EPS came in at -$0.00 , while revenue for the quarter reached $2.93M .
Earnings released on 25 Feb 2024
EPS came in at -$0.00 , while revenue for the quarter reached $309.44K .
Earnings released on 29 Jan 2024
EPS came in at -$0.00 , while revenue for the quarter reached $290.86K .
Stock split effective on 27 Sept 2023
Shares were split 1041 : 1000 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 30 Jun 2023
EPS came in at -$0.00 , while revenue for the quarter reached $1.29M .
Earnings released on 31 Mar 2023
EPS came in at -$0.00 , while revenue for the quarter reached $1.30M .
Earnings released on 30 Dec 2022
EPS came in at -$0.00 , while revenue for the quarter reached $343.10K .
Stock split effective on 5 Dec 2022
Shares were split 50 : 49 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 30 Sept 2022
EPS came in at -$0.00 , while revenue for the quarter reached $325.34K .
Earnings released on 25 Aug 2022
Revenue for the quarter reached $2.55M , beating expectations by +48.00%.
Earnings released on 30 Jun 2022
EPS came in at -$0.00 , while revenue for the quarter reached $1.25M .
Earnings released on 24 Feb 2022
Earnings released on 30 Dec 2021
EPS came in at -$0.00 .
Earnings released on 30 Aug 2021
Earnings released on 30 Jun 2021
EPS came in at -$0.00 .
Earnings released on 24 Feb 2021
EPS came in at -$0.00 , while revenue for the quarter reached $51.17K .
Earnings released on 30 Dec 2020
EPS came in at -$0.00 .
ATGGF Stock Performance
Access detailed ATGGF performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.